PTPN11 and neuroblastoma: Because MAPK hyperactivation is a commonly observed mechanism of neuroblastoma treatment resistance (including against ALK-TKIs; refs. 11, 24, 32), we evaluated whether inactivation of MAPK signaling through SHP2 inhibition could have synergistic effects with ALK-TKIs.